Darwin In the Genome
Education Ph.D, Molecular Biology University of California, Berkeley 1973 B.S. Honors in Chemistry Magna Cum Laude Brooklyn College (City University of New York) 1967 Additional Training: Cold Spring Harbor: Computational Genomics 1992; Genome Informatics 1999
Professional ExperienceRecent Projects 2010- Working Group, Institute for Life Sciences Entrepreneurship 2013- Co-organizer, Evolutionary Dynamics and Information Hierarchies in Biological Systems Aspen, 2012 Adjunct Faculty, St. John’s University 2011 - DIMACS (Center for Discrete Mathematics & Theoretical Computer Science) Rutgers University 2010 – 2011 Visiting Scientist and Conference Chair, Effect of DNA Sequence and Structure on Genome Evolution. Columbia University 2003-2009 2009 Project Specialist, Office of the Vice Dean for Research 2005-2008: Associate Director, Judith P. Sulzberger Genome Center 2004-2005: Executive Director, Center for Computational Biology and Bioinformatics
Initiated and led interdisciplinary initiative across three Columbia University campuses for next-generation DNA sequencing, and wrote and obtained first funding for massively parallel DNA sequencing instruments at Columbia University. Initiated and led network of 15 colleges in establishing Genomics-based Science as Inquiry Initiative.2003: Adjunct Faculty: Genetics
Strategic Advisor 1994-2004 Strategic research advisor to pre-IPO stage biotech, venture capital, and others Responsibilities included: Vice President (consulting), Molecular Mining 1999-2002; Senior Vice President (consulting) Sequoia Sciences 1999-2000; Computational Biology Center, Memorial Sloan-Kettering Cancer Center 2003-2004, Member, Board of Directors and Scientific Advisory Boards, pre- IPO stage companies. Due diligence for VCs and retained by MDS Capital Corp (5/97-4/99).
Special Projects Proposed organized and led several conferences and symposia; these included the landmark conference I proposed, organized and chaired (Co-chair Nobel Laureate Werner Arber, sponsored by NYAS, held at Rockefeller University) and a Symposium at the annual AAAS meeting.
Vice President, Strategic Development, Acting CSO (seed stage) identified and recruited key individuals and mentored the initial research team set a strategic focus distinct from the “first wave” of combinatorial chemistry companies. When “combichem” implied rapid parallel synthesis of huge numbers of uncharacterized molecules, my emphasis was on library design, medicinal chemistry, & high-throughput analysis and purification of reaction products. formulated and negotiated first two major corporate alliances patent for inverse solid phase synthesis
Merck & Co., Inc 1984 - 1994Senior Director, Scientific Liaison. 1992-1994 Defined scientific milestones and represented Merck Research laboratories in negotiations that created strategic relationships with pharmaceutical and biotech companies Responsible for identifying, tracking, and acquiring breakthrough therapeutic agents. Visited with Heads of Research and therapeutic areas heads of multinational pharmaceutical companies. Member, Research Coordinating Committee, responsible for review of all Merck discovery-stage (pre-tox) research programs. Director, Scientific Evaluation 1987-1992
Represented Merck Research Laboratories (MRL) in licensing FOSAMAX® at an early clinical stage, a breakthrough, first-in-class treatment now taken by millions of people for prevention and treatment of osteoporosis. Led an extensive review of mechanisms and compounds for Alzheimer's disease, timed follow-up to match achievement of key "proof of concept" milestones, leading to the identification and licensing-in of a compound by Merck and the recommendation at an early stage in its development that Merck license the compound subsequently licensed by Pfizer and marketed as Aricept®.
Represented Merck Research Labs in structuring the scientific framework for, and negotiation of, the collaboration with Costa Rica's National Biodiversity Institute that increased the molecular diversity of MRL screens, and which became a sustainable development case study at the Harvard Business School. Senior Research Fellow 1984-1987 Conceived and developed expression cloning method for low abundance, hard to purify and/or multisubunit proteins, proposed Merck use this approach to build an effort in what later was called functional genomics. Developed and tested a structural model for a peptide hormone. Increased synthetic yield in automated synthesis of an analogue series by developing lab standard operating procedure involving careful analysis of synthetic byproducts.
Georgetown University Medical Center Assistant Professor of Biochemistry 1978-1984) (Adjunct Faculty, 1984-1988) Designed selective inhibitors of a key enzyme involved in inflammation. Focusing on varied vs. conserved regions of sequence in gene family members to investigate how substrate selectivity is overlaid on a common genetic frameworParticipated in teaching a wide range of courses including Molecular Immunology, Synthetic Organic Chemistry, Medical Biochemistry, and Biochemical Methods. ·Supervised technicians, graduate students, postdoctoral fellows, medical students. A Postdoctoral Fellow in my laboratory was awarded the competitive Mamie Dowd Eisenhower Memorial Fellowship of the American Heart Association. Served on recruitment committees for new faculty and graduate students.
Postdoctoral Experience 1973-1978Rockefeller University Research Associate, Biochemistry 1976-1977 Adjunct Assistant Professor 1978 Defined an active synthetic fragment of the inflammatory peptide C3a Dissected, by organic synthesis, the structural requirements for activity of a key arginine residue Memorial/Sloan-Kettering Cancer Center Associate Researcher, Myelopoiesis 1975-1976 Discovered the existence of distinct colony stimulating factors for different human myelopoeitic lineages. New York University School of Medicine Postdoctoral Fellow, Pathology 1973-74 Demonstrated the importance of germinal centers in the switch to synthesize antibodies directed against thymus-dependent antigens, and the role of IgA as the surface immunoglobulin of cells that home to the secretory immune system.
COURSES TAUGHT Full Courses Scientific Inquiry (nonmajors-St. John’s University), Genetics [Columbia University 2003] Special Topics in Biochemistry [GU], Medical Student Electives [GU], Introductory Chemistry (BC); New courses I created and taught [GU]: Molecular Immunology, Research Rounds Courses team taught [GU]: Medical Biochemistry, Dental Biochemistry, Other courses in which I lectured [GU unless specified]: Biochemical Methods, Medical Immunology, Advanced Immunology, Synthetic Organic Chemistry, Advances in Hematology, Molecular Biology (TA,UCB),Introduction to Molecular Virology (TA UCB), Drug Design (U Mass, Amherst 2000); Tropical Agriculture and Sustainable Development( Columbia, 2007). Introduction to the Biotechnology Industry (2009)
HONORS Advisory Panels/Civic activities Invited Speaker, SMBE session on Molecular Mutation bias and Hypermutability as Factors in Evolution 2014 Discussion Leader & speaker Gordon Research Conference on Biological Mechanisms in Evolution 2013 Co-organizer, Evolutionary Dynamics and Information Hierarchies in Biological Systems; Aspen, 2012 Session Chair Evolution in the Time of Genomics EMBO Conference Venice, Italy 2012 Conference Chair, Effects of Genome Structure and Sequence on the Generation of Variation, 2011 Invited Speaker, Workshop on Evolution: Foundations, Fundamentals and Disease. Hong Kong, 2009 American Museum of Natural History NIH-SEPA advisory panel 2009-2012 Session Chair Cold Spring Harbor Laboratory 74th Symposium: Evolution—The Molecular Landscape 5/27-6/2/2009 Invited Speaker, EmergeNET: Evolution and Emergence; Glasgow, UK 3/09 Invited Speaker, conference on “Stress, Stress Responses, and Mechanisms of Evolvability” Baeza, Spain 10/07 Invited Speaker, conference on Evolvability: the Evolution of Evolution, Villa Monastero, Varenna, 4/07 Moderator, Marian Koshland Science Museum of the National Academies of Sciences, International Darwin Day, Forum on Teaching Evolution in the Classroom 2/12.07 Interviewed by Warren Olney on KCRW’s To the Point,
Jennifer Ludden on NPR’s All Things Considered,
CNN, CNN-fn, several radio stations and by the Associated Press Interviewed on The Women’s Connection http://www.youtube.com/watch?v=mjQ7ZcrJI8Q Lecture marking the 50th Anniversary of the publication of DNA Structure, NYAS 4/03 Panelist, NYBA The Interface between Infotech and Biotech (3/02) Symposium Organizer: Higher-Order Discovery: Getting the most out of complex biological datasets using advanced data analysis and prediction methods. BIO2002 (June 2002) Symposium Chair, Genome Strategies in Evolution and Disease (AAAS 2000) Conference Chair, Molecular Strategies in Biological Evolution 1998
Editorial Board, The Combinatorial Chemistry Journal (John Wiley & Sons) 3/97-99 Scientific Advisory Committee, Molecular Diversity & Combinatorial Chemistry: Applications for Drug Lead Discovery and Chair of Day 1: Combinatorial Chemistry Strategies 1/96, San Diego After the Genome: Measuring, Modeling and Understanding Complex Biological Systems, National Center Genome Resources: Invited Presentation (1995) Organizing Committee (1996) Rainforest Alliance Advisory Panel, Fiji Bioprospecting Project 5/96 Member, IOCD Advisory Committee, Biotic Exploration Fund 7/95 Invited Speaker, National Academy of Sciences meeting of the Committee on Biobased Industrial Products July 8,1994 Georgetown University Biochemistry Department Faculty Search Committee (2 positions)
Program Assistant, International House, Berkeley Dean's Honor List all 8 semesters at Brooklyn College (graduated at age 19) The Scholars’ Program Woodrow Wilson Fellow (Honorary) Phi Beta Kappa Sigma Xi [President of GU chapter] President of Laurel Branch Honor Society BC President of the Chemistry Society of BC All-College Gold Key American Institute of Chemists' Medal, Brooklyn College Grants: awards and review panel membership Member, NIH Physiological Chemistry Study Section 10/1/86-9/30/90 Ad hoc Member, 7 Special NIH Study Sections 1980-84, NSF reviewer [2002, 2007] Principal Investigator, American Lung Association 1978 Detection and Inhibition of Complement-Medicated Inflammation. Principal Investigator, National Institutes of Health. Complement and Inflammation: A Biochemical Approach12/1/78-3/31/87 (Awarded) Principal Investigator Naval Research Labs Biohapten Detection Systems11/82 -12/84 Proposed and wrote successful STTR: Control of Biofilms by Natural Products R42RR016363 Initiated and led successful NIH Shared Instrumentation Grant for Columbia University’s first massively parallel DNA sequencers 2007 involving 20 NIH funded investigators. Co-PI 2011 National Science Foundation award 1062170 Genome Structure and Variation
Books 1. Caporale, L.H., Editor (1999) Molecular Strategies in Biological Evolution. Annals of the New York Academy of Sciences 870 2. Caporale, L.H. (2002) Darwin in the Genome McGraw-Hill, New York. 3. Caporale, L.H. (2006) Editor, The Implicit Genome Oxford University Press 4. Caporale, L.H. Editor (2012). The Effect of DNA Sequence and Structure on Genome Variation in Evolution. Ann. NYAS 1267
Book Chapters 1. Kunkel, S., Ward, P., Caporale, L., and Vogel C-W. (1985). The Complement System. in: Immunology III. 106-116. Ed. J. Bellanti W.B. Saunders, Philadelphia. 2. Caporale, L.H. (1992) Molecular Immunology. in Biochemistry. (textbook) ed. N. Bhagavan. Jones and Bartlett, Portola Valley, California. 3. Caporale, L.H. (1992) The Collaboration Between Merck and INBio in God Money and the Rainforest Center for Environmental Study and the University of Michigan Global Change Project; Grand Rapids, MI 4. Caporale, L.H. (1996) The Merck/INBio Agreement: A Pharmaceutical Company Perspective in
Medicinal Resources of the Tropical Forest: Biodiversity and its Importance to Human Health ed. M. Balick, E. Elisabetsky, and S. Laird. Columbia University Press, New York 5. Caporale, L.H. and Dermody, M.F. Drug Discovery and Biodiversity: Collaborations and Risk in the Discovery of new Pharmaceuticals in J. Feinsilver, editor, published by the Pan American Health Organization (1996)) 6. Caporale, L.H. Using Evolution to Discover New Drugs in Cracraft, J. and R. Bybee (eds.). 2005. Evolutionary Science and Society: Educating a New Generation. Biological Sciences Curriculum Study, Colorado Springs, CO 7. Caporale, L.H (2006) An Overview of The Implicit Genome in The Implicit Genome Oxford University Press 8. Doyle, J., Csete. M. and Caporale, L.H. (2006) An Engineering Perspective: The Implicit Protocols in The Implicit Genome Oxford University Press.
Articles 1. Caporale, Lynn H. (1973). Studies on Rabbit Colostral IgA and its J. Chain. Ph.D. Thesis, University of California, Berkeley. 2. Mond, James J., Caporale, Lynn H., and Thorbecke, G. Jeanette (1974). Kinetics of B Cell Memory Development during a Thymus 'Independent' Immune Response. Cellular Immunology 10: 105-116. 3. Jacobson, E.G., Caporale, Lynn H., and Thorbecke, G. Jeanette (1974). Effect of Thymus Cell Injections on Germinal Center Formation in Lymphoid Tissues of Nude (Thymusless) Mice. Cellular Immunology 13: 416-430. 4. Durkin, Helen G., Caporale, Lynn H., and Thorbecke, G. Jeanette (1975). Migratory Patterns of B Lymphocytes. Fate of Cells from Central and Peripheral Organs in the Rabbit and its Selective Alteration by Anti-Immunoglobulin. Cellular Immunology 16: 285-300. 5. Shah, R., Caporale, L.H., and Moore, M.A.S. (1977). Characterization of Granulocytic Colony Stimulating Activity Produced by Human Monocytes and PHA Stimulated Lymphocytes. Blood 50: 811-821. 6. Caporale, Lynn H., Erickson, Bruce W., and Hugli, Tony E. (1977). Synthetic Oligopeptides from Human C3a Anaphylatoxin that Mediate the Inflammatory Response. In: Peptides, pp. 225-227. Eds. M. Goodman and J. Meienhofer (Halsted Press, N.Y.). 7. Caporale, Lynn H., Tippett, Peter S., Erickson, Bruce W., and Hugli, Tony E. (1980). The Active Site of C3a Anaphylatoxin. J. Biol. Chem. 255: 10758-10763. 8. Caporale, L.H.,Gutierrez, J.C., and Gotze, O. (1981). An Improved Peptide Substrate for CVFBb. In: Peptides, pp. 421-424. Eds. D. Rich and E. Gross. Proceedings of the Seventh American Peptide Symposium. 9. Caporale, Lynn H., Gaber, Sung-Suk, Kell, Wayne, and Gotze, Otto (1981). A Fluorescent Assay for Complement Activation. J. Immunol. 126: 1963-1965. 10. Caporale, Lynn H. (1981). Leupeptin Inhibits the C3/5 Convertase CVFBb of the Complement System. Biochem. Biophys. Acta 660: 151-153. 11. Gutierrez, J.C., Gotze, O., and Caporale, L.H. (1983). An improved Fluorogenic Substrate for the Alternative Complement Pathway C3/5 Converting Enzyme CVF-Bb. Biochem. Biophys. Acta 744: 276-280. 12. Caporale, L.H. (1984). Is There a Higher Level Genetic Code that Directs Evolution? Mol. Cell. Biochem. 64: 5-13. 13. Feldmann, R.J., Bing, D.H., Potter, M., Mainhart, C., Furie, B.C., and Caporale, L.H. (1985). On the Construction of Computer Models and Proteins by the Extension of Crystallographic Structures. Ann. N.Y. Acad. Sci. 439: 12-43. 14. Caporale, L., DeHaven, P. Fisher, J., Tyler G., and Rosenblatt, M. Discrimination Between Parathyroid Hormone (PTH) Agonists and Antagonists In Vitro: Modification of the Renal Membrane Adenylate Cyclase Assay to Reflect In Vivo Activity of PTH Analogs. In: Peptides: Structure and Function. Eds. Deber, C.M., Hruby V.J., and Kopple, K.D. (Proceedings of the Ninth American Peptide Symposium, Toronto, Canada, June 23-28, 1985). Pierce Chemical Company, Rockford, pp. 663-666, 1985. 15. Caporale, L.H.and Rosenblatt, M. (1986). Parathyroid Hormone Antagonists Effective In Vivo. Adv. Exp. Med. Biol. 208:315-327. 16. Caporale, L.H. and Rosenblatt, M.R. (1986). Parathyroid Hormone Secretion; Molecular Events and Regulation. Contrib. Nephrol. 50: 73-95. 17. Caporale, l., R. Nutt, J. Levy, M. Rosenblatt, J. Smith, B. Arison, W. Randall, C. Bennett, G. Albers-Schonberg, S. Pitzenberger, and R. Hirschmann (1986). Characterization of Synthetic Peptide Hormone Analogs and of By-Products. Peptides 1986: 223-226. Ed. Theodoropoulos, D., de Gruyter, Berlin. 18.Wright, B.S., Tyler, G.A., O'Brien, R., Caporale, L.H. and Rosenblatt, M. (1987). Immunoprecipitation of the Parathyroid Hormone Receptor. Proc. Natl. Acad. Sci. USA 84: 26-30. 19. Tosteson, Magdalena T. , Jay J. Levy, Lynn H. Caporale, Michael Rosenblatt, and Daniel C.Tosteson (1987). Solid-Phase Synthesis of Melittin: Purification and Functional Characterization. Biochemistry 26: 6627-6631. 20. Caporale, Lynn H., Michael Chorev, Jay J. Levy, Mark E. Goldman, Patricia A. DeHaven, C. Thomas Gay, Jane E. Reagan, Michael Rosenblatt, and Ruth F. Nutt. Characterization of Parathyroid Hormone Antagonist. Peptides (1988), pp. 449-451. Marshall, G., ESCOM Science Publishers, Netherlands. 21. O'Keefe, M. Clare, Lynn H. Caporale, and Carl-Wilhelm Vogel (1988). A Novel Cleavage Product of Human Complement Component C3 with Structural and Functional Properties of Cobra Venom Factor. J. Biol. Chem. 263(25): 12690-12697. 22. Caporale, L., Nutt, R., Levy, J., Smith, J., Arison, B., Bennett, C., Albers-Schonberg, G., Pitzenberger, S., Rosenblatt, M., and Hirschmann, R. (1989). Characterization of Synthetic Parathyroid Hormone Analogues and of Synthetic By-Products. J. Org. Chem. 54: 343. 23. Chorev, Michael, Mark E. Goldman, Roberta L. McKee, Eliahu Roubini, Jay J. Levy, C. Thomas Gay, Jane E. Reagan, John E. Fisher, Lynn H. Caporale, Ellis E. Golub, Michael P. Caulfield, Ruth F. Nutt, and Michael Rosenblatt (1990). Modifications of Position 12 in Parathyroid Hormone and Parathyroid Hormone-Related Protein: Toward the Design of Highly Potent Antagonists. Biochemistry 29: 1580-1586. 24. Caporale, L.H., Chartrain, N., Tocci, M., and DeHaven, P. (1990). Protoplast Fusion in Microtiter Plates for Expression Cloning in Mammalian Cells: demonstration of Feasibility Using Membrane-Bound Alkaline Phosphatase as a Reporter Enzyme. Gene 87:285-289. 25. Berkovich, Alla, M. Clare O'Keefe, Preston Hensley, and Lynn Caporale (1990). Effect of N-Methylation on the Modulation by Synthetic Peptides of the Activity of the Serine Protease CVFBb. Biochemical J. 270.531-537 26. Tosteson, M.T,. O. Alvarez, W. Hubbell, R.M. Bieganski, C. Attenbach, L.H. Caporale, J.J. Levy, R.F. Nutt, M. Rosenblatt, and D.C. Tosteson (1990). Primary Structure of Peptides and Ion Channels: Role of Amino Acid Side Chains in Voltage Gating of Melittin Channels. Biophys J 1990;58:1367-1375. 27. Caporale, L.H. and DeHaven, P. (1993) Expression Cloning of Rare Gene Products by Protoplast Fusion in Mammalian Cells J. Tiss. Cult. Meth. 15:69-71. [invited contribution] 28. Caporale, L.H. (1995) Chemical Ecology: A View from the Pharmaceutical Industry, Proc. Natl. Acad. Sci. US 92:75-82 (also published in a book, Chemical Ecology, ed. T. Eisner and J. Meinwald, National Academy Press) 29. Caporale, L.H. (1995) The importance of biodiversity. Defenders 70:16 30. Tarby, C. Myers, P., Caporale, Lynn and Boger, Dale (1996) Generalized Dipeptidemimetic Template: Solution Phase Parallel Synthesis of Combinatorial Libraries J. Am. Chem. Soc. 118, 2109-2110 31. Cheng, S., Tarby, C.M., Comer, D. D., Williams, J.P. , Caporale, L.H., Myers, P. L., and Boger, D. L. (1996) A Solution -Phase Strategy for the Synthesis of Chemical Libraries Containing Small Organic Molecules: A Universal and Dipeptide Mimetic Template Bioorg. Med. Chem. 4 727 32. Caporale, L. (1998) Do Genomes Facilitate their own Evolution: A meeting brief. In HMS Beagle: The BioMedNet Magazine Issue 36 (Aug. 7). (http://biomednet.com/hmsbeagle/36/resnews/meeting.htm) 33. Caporale, L.H. (1998) Lessons from the Most Innovative Genetic Engineers. Nature Biotechnology 16 (10) 908-909 34. Caporale, L.H. (1999) Chance Favors the Prepared Genome in AnnNYAS870:1-21 35. Caporale L.H. (2000) Mutation is Modulated: Implications for Evolution BioEssays 22:388-395. 36
.Caporale, L.H. (2003) Foresight in Genome Evolution American Scientist 91:234-241 37. Caporale, L.H. (2003) Natural Selection and the Emergence of a Mutation Phenotype. Annual Review Microbiology 57: 467-85 38.
Caporale, L.H. (2005) Using Evolution to Discover New Drugs in Evolutionary Science and Society: Educating a New Generation. J. Cracraft and R. Bybee editors, American Institute of Biological Sciences, Washington, DC. 39. Caporale L. H. (2005) Darwin in the genome. BioEssays. 27:984
Caporale, L. H. (2008) It’s not random anymore. BioEssays 30: 400-402
Caporale, L. H. (2009) Putting together the pieces: Evolutionary Mechanisms at Work within Genomes. BioEssays 31:700-70209
Banta, L. M.., Crespi,E.J., Nehm,R.H., Schwarz,J.A., Singer,S., Manduca,C.A., Bush,E.C., Collins,E., Constance,,C.M., Dean,D., Esteban,D., Fox,S., McDaris,J., Paul,C.A. Quinan,G. Raley-Susman, K.M., Smith,M.L., Wallace,C.S., Withers,G.S., and Lynn Caporale (2012) Integrating Genomics Research throughout the Undergraduate Curriculum: A Collection of Inquiry-Based Genomics Lab Modules CBE—Life Sciences Education Vol. 11, 203–208, Fall 2012
Caporale, L.H. (2012) Overview of The Effect of Genome Sequence and Structure on the Generation of Variation and Evolution. Annals NYAS 1267:1-10. doi:10.1111/j.1749-6632.2012.06749.x.
Caporale, L.H. and Doyle, J. (2013) In Darwinian evolution, feedback from natural selection leads to biased mutations. Annals NYAS Sep 13. doi: 10.1111/nyas.12235.
Abstracts 1. Broxmeyer, H.E., Caporale, L.H., Galbraith, P.R., and Moore, M.A.S. (1975). Soluble Colony Inhibiting Activity (CIA) derived from Human Polymorphonuclear Leukocytes (PMN). Blood 46: 1009 (Abs.). 2. Caporale, Lynn H., Erickson, Bruce W., and Hugli, Tony E. (1978). Synthetic Oligopeptides with the Activity of Human C3a Anaphylatoxin. (Abs.) 7th International Complement Workshop. J. Immunol. 120: 1767. 3. Caporale, Lynn H., Erickson, Bruce W., and Hugli, Tony E. (1979). The Role of the Carboxyl Terminal Arginine in the Activity of Human C3a Anaphylatoxin. (Abs.) XIth International Congress of Biochemistry. 4. Erickson, Bruce W., Caporale, Lynn H., Fox, Kam-Fook, Unson, Cecelia, and Hugli, Tony. The Active Site of C3a Anaphylatoxin. (Abs.) 8th International Complement Workshop. J. Immunol. 124: 1519 (1980). 5. Caporale, Lynn H., Gaber, Sung-Suk, Gutierrez, Joanne, and Gotze, Otto (1980). A Fluorescent Substrate for CVFBb and Its Use to Demonstrate Inhibition of C3 Convertase by Leupeptin. (Abs.) Fourth International Congress of Immunology. 6. Caporale, L., Gutierrez, J., Flaherty J., Kelley, L., and Goetze, O. (1982). Fluorogenic Substrates for Complement Factor Bb. Mol. Immunol. 19(11): 1363. 7. Kell, Wayne, Lake, Phil, and Caporale, Lynn (1983). EBV-transformed B-Cell Lines Selectively Bind and Respond to a Mitogen-Induced Soluble Lymphoid Factor Distinct from IL-2. Fed. Proc. 42: 409 8. Caporale, Lynn H., Arlaud, Gerard J., Gagnon, Jean, and Bing, David (1983). A Computer-Generated 3-Dimensional Model of Serine Protease Subunit of Human Clr, Subcomponent of the First Component of Complement. Immunobiology 164: 221. 9. Caporale, Lynn H., Woods, Derek, Gagnon, Jean, Christie, David, and Bing, David (1983). A Computer-Generated Model of the Serine Proteinase Domain of Human Complement Factor B. Immunobiology 164: 213. 10. O'Keefe, M. Clare, Vogel, Carl-Wilhelm, and Caporale, Lynn (1984). Characterization of a Protease from Cobra Venom that Cleaves the Human Complement Component C3. Fed. Proc. 11. Caporale, Lynn, O'Keefe, M. Clare, and Vogel, Carl-Wilhelm (1984). C3o, A New Cleavage Product of Human C3 Generated by a Protease from Cobra Venom. Fed. Proc. 43: 1448. 12. Berkovich, Alla, O'Keefe, M. Clare, Hensley, Preston, and Caporale, Lynn (1984). Differential Effects of Small Peptides on Hemolytic and Peptidase Activity of CVFBb of the Alternative Pathway of Complement. Fed. Proc. 13. Caporale, L., DeHaven, P., Tyler, G. and Rosenblatt, M. (1985). Discrimination Between Parathyroid Hormone (PTH) Agonists and Antagonists In Vitro: Modification of the Renal Membrane Adenylate Cyclase Assay to Reflect In Vivo Activity of PTH Analogs. (Abs.) J. Bone & Min. Res. 1 (1):136, 1986 14. O'Keefe, M.C., Caporale, L.H., and Vogel, C-W. (1985). Structural and Functional Characterization of a Human Analog of Cobra Venom Factor. Complement 2: 58-59. 15. Wright, B., Tyler, G., Caporale, L.H., and Rosenblatt, M. (1986). Immunoprecipitation of the Parathyroid Hormone Receptor. Fed. Proc. 45: #1489. 16. Wright, B.S., Tyler, G.A., O'Brien, R., Caporale, L.H., and Rosenblatt, M. (1986). Immunoprecipitation of the Parathyroid Hormone Receptor. Abstracts of the American Society of Bone and Mineral Research. 17. DeHaven, P., Fisher, J., Levy, J., Nutt, R., Rosenblatt, M., and Caporale, L. (1987). Effectiveness of New Parathyroid Hormone Antagonists. The Observed Potency Varies Across Agonist Dose-Response Curve. Fed. Proc. 46(6): 2193. 18. Rosenblatt, M., Chorev, M., Caporale, L.H., DeHaven, P.A., Fisher, J.E., Gay, C.T., Goldman, M.E., Levy, J.J., Nutt, R.F., Reagan, J.E., Tyler, G.A., and Wright, B.S. (1987). Parathyroid Hormone Antagonists and Receptor Interaction. Program of the First International Conference on New Actions of Parathyroid Hormone, Kobe, Japan, October 26-31, 1987. 19. Chorev, M., Goldman, M.E., Reagan, J.E., DeHaven, P., Levy, J.J., Nutt, R.F., Caporale, L.H., and Rosenblatt, M. (1987). Characterization of Novel Parathyroid Hormone (PTH) Analogs Using An Improved 125I PTH Binding Assay. Abstracts of the Tenth American Peptide Symposium. 20. Goldman, M.E., Chorev, M., Reagan, J.E., Caporale, L.H., and Rosenblatt, M. (1987). Optimization of [125I] Parathyroid Hormone Binding to Bovine Renal Cortex Membranes and Characterization of New Analogs. J. of Bone and Mineral Research 2 (Supplement I): 284. 21. Chorev, M. .,M.E. Goldman, L.H. Caporale, J.J. Levy, J.E. Reagan, P. DeHaven, T. Gay, R.F. Nutt, and M. Rosenblatt (1987). Probing the Conformation of a Parathyroid Hormone Agonist (1-34) and Antagonist (7-34) by Studying the Effect of Single Amino Acid Substitutions on Biological Activity. (Japan Symposium on Peptide Chemistry, Kobe, Japan, 9/28-10/2, 1987)In: Peptide Chemistry 1987. Eds. Shiba, T. & Sakakibara S. Protein Research Foundation, Osaka, pp. 621-626, 1988. 22.O'Keefe, M.C., Caporale, L.H., Vogel, C-W. (1987). Comparison of the Alpha Chain Fragments of C3o, C3c and CVF Implications for C3 Convertase Formation. Complement 4: 204. 23. Tosteson, M.T., Caporale, L.H., and Tosteson, D.C. (1988). Structure-Function Relationships in Peptide-Induced Ion Channels. Biophysical J. 53: 9a. 24. Caporale, L. Collaborations to Find Medicines in Tropical Forests: A Pharmaceutical Company Perspective. Roundtable at 19th Annual National Council on International Health Conference: A Global Partnership: Improving the Health of Underserved Populations. Arlington, VA June 1992 25. Caporale, L.H. (1995) Theme and Variations in the Genome presented at After the Genome National Center for Genome Resources, 10/95 26. Caporale, L.H. (1996) Myriad Molecules. Presented at forum on Drug Discovery in the 21st Century; AAAS, Baltimore 2/9/96 27. Caporale, L.H. (1996) A systematic approach to the discovery of biologically-active molecules: drugs and research tools. Presented at After the Genome 2: Towards a Predictive Functional Genomics; National Center for Genome Resources, 11/96 28. Caporale, L.H. (1997) Does DNA encode information that modulates its rate of evolution? Presented at: Junk DNA: the role and the evolution of non-coding sequences: a Symposium in honor of Emile Zuckerkandl; International Society of Molecular Evolution. 29. Caporale, L.H. (1998) Does DNA encode information that modulates its rate of evolution? Interjournal (an on-line journal ) (http://www.ceptualinstitute.com/genre/caporale/Caporale_IJ2.htm) 30. Caporale, L.H. (1999) Evolution of Efficient strategies for evolution: Chance Favors the Prepared Genome ICCS ed. Y. Bar-Yam (on-line at http://www.ceptualinstitute.com/genre/caporale/LHCnecsi.htm) 31. Caporale, L.H. (1999) Molecular Strategies in Biological Evolution. Presented at: Evolutionary Genomics, an international conference organized by Giorgio Bernardi, Gabriel Macaya and Takashi Gojobori 32. Zeng, L., Cremin, P., Lee, C., O’Neil-Johnson, M, and Caporale, L. (2001) High throughput natural product chemistry for drug discovery. 221st meeting of the American Chemical Society 33. Roland Somogyi, Alan Ableson, Max Kotlyar, Ross Dickson, Lynn Caporale [presenter], Evan Steeg, Larry Greller A Systems Approach to post-genomic biological analysis CSHL Symposium Integrating Genome Sequence, Sequence Variation and Gene Expression 9/28-30/2001
34. Roland Somogyi, Alan Ableson, Max Kotlyar, Bernard Chang, Ross Dickson, Stefanie Fuhrman, Lynn Caporale, Evan Steeg, Larry Greller Exploration, Inference, Prediction: getting the most out of your data from target discovery to validation. CHI High-Throughput Target Validation, Boston, November 14, 2001
35. Lynn Caporale : The Evolution of Evolution: Towards a Genomic Synthesis for Evolutionary Theory; invited presentation, conference on Evolvability: the Evolution of Evolution, Villa Monastero, Varenna, organized by Simon Conway Morris, Ard Louis et al. (2007)
36.Lynn Caporale (2009): A Genomic Synthesis for Evolutionary Theory: Mutation is Not Random http://videochannel.ust.hk/Watch.aspx?Video=39AC69D03A6742D2
Issued Patents 1. M. Rosenblatt, L. Caporale, R. Nutt, J. Levy, and M. Chorev. U.S. Patent No. 4,771,124. Case No. 17583-USSN 054,359. Filed 5/26/87. Issued 9/13/88. For: Parathyroid Hormone Antagonists with Simplified Synthetic Methodology 2. L. H. Caporale U.S. Patent No. 5,767,238 Filed June 7, 1995; Issued June 16, 1998 For: Inverse solid phase synthesis